Trial | NCT00689598  Report issue

Title

Spironolactone for Paroxysmal Atrial Fibrillation
Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    30
To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.
To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.
Study Started
Mar 31
2008
Primary Completion
Mar 31
2011
Anticipated
Study Completion
Mar 31
2011
Anticipated
Last Update
Jun 05
2008
Estimate

Drug Spironolactone

25 mg po qd 25 mg po bid

  • Other names: Aldactone

Drug Placebo

Spironolactone 25 mg po qd

  • Other names: Aldactone

III Placebo Comparator

Placebo

Experimental Experimental

Drug intervention

Criteria 

Inclusion criteria:

18 to 80 Y/O,
Paroxysmal AF.

Exclusion criteria:

GPT>100 IU/L or tota bilirubin >2 mg/dl;
Creatinine > 2 mg/dl;
Serum potassium >= 5 mM;
Serum sodium <=130 mM;
Uric acid > 10 mg/dl。
No Results Posted